References
- FisherBCostantinoJRedmondCA randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumorsN Engl J Med19893208479484
- FisherBDignamJWolmarkNTamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancerJ Natl Cancer Inst19978922167316829390536
- FisherBJeongJHBryantJNational Surgical Adjuvant Breast and Bowel Project randomised clinical trialsTreatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trialsLancet20043649437858868
- HornbergerJCoslerLELymanGHEconomic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancerAm J Manag Care2005115313324
- OestreicherNRamseySDLindenHMGene expression profiling and breast cancer care: what are the potential benefits and policy implications?Genet Med200576380389
- LymanGHCoslerLEKudererNMHornbergerJImpact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studiesCancer2007109610111018
- KondoMHoshiSLIshiguroHYoshibayashiHToiMEconomic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in JapanBreast Cancer Res Treat2008112117518718075786
- ChenETongKBMalinJLCost-effectiveness of 70-gene MammaPrint signature in node-negative breast cancerAm J Manag Care20101612e333e34221291290
- KlangSHHammermanALiebermannNEfratNDoberneJHornbergerJEconomic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organizationValue Health201013438138720412544
- RetèlVPJooreMAKnauerMLinnSCHauptmannMHartenWHCost-effectiveness of the 70-gene signature versus St Gallen guidelines and Adjuvant Online for early breast cancerEur J Cancer20104681382139120359886
- TsoiDTInoueMKellyCMVermaSPritchardKICost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancerOncologist201015545746520421264
- OlivottoIABajdikCDRavdinPMPopulation-based validation of the prognostic model ADJUVANT! for early breast cancerJ Clin Oncol200523122716272515837986
- YangMRajanSIssaAMCost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic modelCancer2012118205163517022359236
- PaikSTangGShakSGene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancerJ Clin Oncol2006242337263734
- RossDTKimCYTangGChemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trialsClin Cancer Res200814206602660918927301
- BartlettJMThomasJRossDTMammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapyBreast Cancer Res2010124R4720615243
- TangGShakSPaikSComparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20Breast Cancer Res Treat2011127113314221221771
- WeinsteinMCO’BrienBHornbergerJISPOR Task Force on Good Research Practices – Modeling StudiesPrinciples of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices – Modeling StudiesValue Health20036191712535234
- Genomic Health IncForm 10-Q: Quarterly Report Pursuant to Section 13 or 15(D) the Securities and Exchange Act of 1934Redwood City, CAGenomic Health, Inc2012 Available from: http://investor.genomichealth.com/secfiling.cfm?filingID=1104659-12-76632&CIK=1131324Accessed February 14, 2013
- US Department of Health and Human Services2012 Annual Progress Report to Congress. National Strategy for Quality Improvement in Health CareWashington, DCUS Department of Health and Human Services2012 Available from: http://www.ahrq.gov/workingforquality/nqs/nqs2012annlrpt.pdfAccessed February 14, 2013
- DonnellyJHealth policy briefs: comparative effectiveness research [homepage on the Internet]Health Affairs2010 [updated October 5, 2010]. Available from: http://www.healthaffairs.org/healthpolicybriefs/brief.php?brief_id=27Accessed October 4, 2013
- JemalASiegelRXuJWardECancer statistics, 2010CA Cancer J Clin201060527730020610543
- AriasEUnited States Life Tables, 2008National Vital Statistics Reports2008569Centers for Disease Control and Prevention, National Center for Health StatisticsHyattsville, MD Accessed online at http://www.cdc.gov/nchs/products/pubs/pubd/nvsr/nvsr.htmAccessed February 14, 2013